| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 12282* | 2021 |
| Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma BE Johnson, T Mazor, C Hong, M Barnes, K Aihara, CY McLean, ... Science 343 (6167), 189-193, 2014 | 1501 | 2014 |
| A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling ZA Knight, B Gonzalez, ME Feldman, ER Zunder, DD Goldenberg, ... Cell 125 (4), 733-747, 2006 | 1425 | 2006 |
| Intertumoral heterogeneity within medulloblastoma subgroups FMG Cavalli, M Remke, L Rampasek, J Peacock, DJH Shih, B Luu, ... Cancer cell 31 (6), 737-754. e6, 2017 | 1172 | 2017 |
| miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells J Silber, DA Lim, C Petritsch, AI Persson, AK Maunakea, M Yu, ... BMC medicine 6, 1-17, 2008 | 1163 | 2008 |
| Principles and current strategies for targeting autophagy for cancer treatment RK Amaravadi, J Lippincott-Schwartz, XM Yin, WA Weiss, N Takebe, ... Clinical cancer research 17 (4), 654-666, 2011 | 1049 | 2011 |
| Targeted expression of MYCN causes neuroblastoma in transgenic mice WA Weiss, K Aldape, G Mohapatra, BG Feuerstein, JM Bishop The EMBO journal, 1997 | 1042 | 1997 |
| Subgroup-specific structural variation across 1,000 medulloblastoma genomes PA Northcott, DJH Shih, J Peacock, L Garzia, A Sorana Morrissy, ... Nature 488 (7409), 49-56, 2012 | 1015 | 2012 |
| Neuroblastoma and MYCN M Huang, WA Weiss Cold Spring Harbor perspectives in medicine 3 (10), a014415, 2013 | 768 | 2013 |
| A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma QW Fan, ZA Knight, DD Goldenberg, W Yu, KE Mostov, D Stokoe, ... Cancer cell 9 (5), 341-349, 2006 | 768 | 2006 |
| Targeting MYCN in neuroblastoma by BET bromodomain inhibition A Puissant, SM Frumm, G Alexe, CF Bassil, J Qi, YH Chanthery, ... Cancer discovery 3 (3), 308-323, 2013 | 736 | 2013 |
| Epigenomic alterations define lethal CIMP-positive ependymomas of infancy SC Mack, H Witt, RM Piro, L Gu, S Zuyderduyn, AM Stütz, X Wang, ... Nature 506 (7489), 445-450, 2014 | 667 | 2014 |
| Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies Z An, O Aksoy, T Zheng, QW Fan, WA Weiss Oncogene 37 (12), 1561-1575, 2018 | 628 | 2018 |
| Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma H Witt, SC Mack, M Ryzhova, S Bender, M Sill, R Isserlin, A Benner, ... Cancer cell 20 (2), 143-157, 2011 | 581 | 2011 |
| Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma N Zhukova, V Ramaswamy, M Remke, E Pfaff, DJH Shih, DC Martin, ... Journal of Clinical Oncology 31 (23), 2927-2935, 2013 | 542 | 2013 |
| Clonal selection drives genetic divergence of metastatic medulloblastoma X Wu, PA Northcott, A Dubuc, AJ Dupuy, DJH Shih, H Witt, S Croul, ... Nature 482 (7386), 529-533, 2012 | 494 | 2012 |
| Pediatric high-grade glioma: biologically and clinically in need of new thinking C Jones, MA Karajannis, DTW Jones, MW Kieran, M Monje, SJ Baker, ... Neuro-oncology 19 (2), 153-161, 2017 | 416 | 2017 |
| BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma P Bandopadhayay, G Bergthold, B Nguyen, S Schubert, S Gholamin, ... Clinical Cancer Research 20 (4), 912-925, 2014 | 402 | 2014 |
| Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis EM Thompson, T Hielscher, E Bouffet, M Remke, B Luu, S Gururangan, ... The lancet oncology 17 (4), 484-495, 2016 | 399 | 2016 |
| Recognizing and exploiting differences between RNAi and small-molecule inhibitors WA Weiss, SS Taylor, KM Shokat Nature chemical biology 3 (12), 739-744, 2007 | 373 | 2007 |
